인쇄하기
취소

Amgen Korea announces approval of Blincyto as acute lymphoblastic leukemia treatment

Published: 2015-12-07 14:50:48
Updated: 2015-12-07 14:50:48

Amgen Korea announced commercialization approval of Blincyto Inj 35μg(generic name: blinatumomab), an acute lymphoblastic leukemia (ALL: Acute Lymphoblastic Leukemia) treatment, as a treatment of Philadelphia chromosome-negative or refractory precursor B-cell acute lymphoblastic leukemia from the Ministry of Food and Drug Safety.

A treatment cycle of Blincyto consists of 4-week intravenous adm...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.